New
HealthMore in Health→
Oral Microbiome Therapy Shows Early Signal Against Bloodstream Infections After Stem Cell Transplants
Key Takeaways
- Phase 1b trial compared SER-155 with placebo in a randomized transplant cohort.
- Bloodstream infections occurred in 10.0% of the SER-155 arm versus 43% of placebo recipients.
- The product was well tolerated, but larger trials are needed to confirm clinical benefit.
DE
DT Editorial Team··via nature.com